Triple functional mild photothermal improves gene editing of PD-L1 for enhanced antitumor immunity.

[1]  Yujun Song,et al.  Controlled CRISPR-Cas9 Ribonucleoprotein Delivery for Sensitized Photothermal Therapy. , 2021, Small.

[2]  Islam A Khalil,et al.  Cancer immunotherapy from biology to nanomedicine. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[3]  C. W. Shields,et al.  Magnetic systems for cancer immunotherapy , 2021, Acta pharmaceutica Sinica. B.

[4]  H. Pan,et al.  Reprogramming the Tumor Microenvironment through Second‐Near‐Infrared‐Window Photothermal Genome Editing of PD‐L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy , 2021, Advanced materials.

[5]  Z. Shao,et al.  Solutions to the Drawbacks of Photothermal and Photodynamic Cancer Therapy , 2021, Advanced science.

[6]  E. Calvo,et al.  Clinical Challenges of Immune Checkpoint Inhibitors. , 2020, Cancer cell.

[7]  Jianliang Shen,et al.  Multifunctional magnetic iron oxide nanoparticles: an advanced platform for cancer theranostics , 2020, Theranostics.

[8]  Xingyu Jiang,et al.  Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing. , 2020, Advanced drug delivery reviews.

[9]  Jiajing Zhou,et al.  Mesoporous polydopamine with built-in plasmonic core: Traceable and NIR triggered delivery of functional proteins. , 2020, Biomaterials.

[10]  Y. Ping,et al.  Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing , 2020, Proceedings of the National Academy of Sciences.

[11]  Shasha He,et al.  Photolabile Semiconducting Polymer Nanotransducer for Near-infrared Regulation of CRISPR/Cas9 Gene Editing. , 2019, Angewandte Chemie.

[12]  Zhen Gu,et al.  Rational designs of in vivo CRISPR-Cas delivery systems. , 2019, Advanced drug delivery reviews.

[13]  Yining Zhu,et al.  Combination of Bacterial‐Photothermal Therapy with an Anti‐PD‐1 Peptide Depot for Enhanced Immunity against Advanced Cancer , 2019, Advanced Functional Materials.

[14]  W. Gu,et al.  PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition , 2019, Front. Immunol..

[15]  Wei Cheng,et al.  Versatile Polydopamine Platforms: Synthesis and Promising Applications for Surface Modification and Advanced Nanomedicine. , 2019, ACS nano.

[16]  W. Miller,et al.  A review of cancer immunotherapy: from the past, to the present, to the future. , 2019, Current oncology.

[17]  Hongqi Tian,et al.  Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy , 2019, Journal of drug targeting.

[18]  C. Bettinger,et al.  Polydopamine Nanostructures as Biomaterials for Medical Applications. , 2018, Journal of materials chemistry. B.

[19]  F. Yull,et al.  Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy , 2018, Cancers.

[20]  S. Son,et al.  Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer , 2018, Nature Communications.

[21]  A. Iyer,et al.  PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..

[22]  Lucas B. Harrington,et al.  A thermostable Cas9 with increased lifetime in human plasma , 2017, bioRxiv.

[23]  Aiguo Wu,et al.  Iron Oxide Nanoparticle Based Contrast Agents for Magnetic Resonance Imaging. , 2017, Molecular pharmaceutics.

[24]  A. Sharpe.  Introduction to checkpoint inhibitors and cancer immunotherapy , 2017, Immunological reviews.

[25]  S. Sarcar,et al.  Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9 , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  Toby C. Cornish,et al.  PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. , 2016, Human pathology.

[27]  C. Hunter,et al.  IL-6 as a keystone cytokine in health and disease , 2015, Nature Immunology.

[28]  Ligeng Xu,et al.  Immunological Responses Triggered by Photothermal Therapy with Carbon Nanotubes in Combination with Anti‐CTLA‐4 Therapy to Inhibit Cancer Metastasis , 2014, Advanced materials.

[29]  M. Tadé,et al.  Synthesis of nitrogen-doped mesoporous carbon spheres with extra-large pores through assembly of diblock copolymer micelles. , 2014, Angewandte Chemie.

[30]  Liang Cheng,et al.  Functional nanomaterials for phototherapies of cancer. , 2014, Chemical reviews.

[31]  Daesik Kim,et al.  Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.

[32]  Gang Bao,et al.  CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences , 2014, Nucleic acids research.

[33]  Jeffry D. Sander,et al.  CRISPR-Cas systems for editing, regulating and targeting genomes , 2014, Nature Biotechnology.

[34]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[35]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[36]  G. Schuler,et al.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. , 1999, Journal of immunological methods.

[37]  M. Croft,et al.  A direct role for IFN-gamma in regulation of Th1 cell development. , 1996, Journal of immunology.

[38]  G. Camussi,et al.  The molecular action of tumor necrosis factor‐α , 1991 .

[39]  D. Gammack,et al.  A SIMPLE METHOD FOR THE QUANTITATIVE ISOLATION OF UNDEGRADED HIGH MOLECULAR WEIGHT RIBONUCLEIC ACID. , 1963, Biochemical and biophysical research communications.

[40]  H. McLeod,et al.  Assessment of Adverse Events and Their Ability to Discriminate Response to Anti-PD-1/PD-L1 Antibody Immunotherapy. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.